TearClear

Private

Newport Beach, CaliforniaHealthcare & Life Scienceshttp://tearclear.com/

Last Round

Series C

Jun 28, 2023

Total Funding Raised

$51.95M

Company Overview

TearClear is a life sciences company that develops ophthalmic drugs intended to transform trusted ophthalmic medications into preservative-free therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

ophthalmic pharmaceuticaldrug delivery technologypreservative-free eye dropsbenzalkonium chlorideBAKhydrogel filterglaucoma treatmentdry eye therapydrug-device combination505(b)(2) pathwayophthalmologyeye care innovationmedtechtopical medication

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TearClear Comps

Public and private peers based on sector, stage, and business model.

TearClear comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TearClear Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	Jun 28, 2023
Debt	Aug 2, 2022
Series B	Aug 11, 2020
Debt	Jan 31, 2020
Series A Extension	Feb 1, 2019
Series A	May 30, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Srini Venkatesh

Chief Executive Officer

Executive Team

TearClear Investors

Notable investors and investment history

TearClear investors
Investor	Rounds
Kohlberg Kravis Roberts	Series B
Flying L Partners	Series B
Falcon Vision	Series B
KKR	Series B
Visionary Ventures	Series B, Series A Extension, Series A
Bluestem Capital	Series B, Series A Extension, Series A

View all Investors

TearClear Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

TearClear Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TearClear's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewport Beach, California

Employee Range6

Year Founded2015

Last FundingJun 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.